MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide – approved by US and European regulators for a rare light intolerance disorder – is being evaluated by Australian company CLINUVEL as a treatment for vitiligo patients with darker skin types.
CLINUVEL progresses vitiligo treatment program
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20badge%20holder-by%20hasrul_rais%20via%20Shutterstock.jpg)
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
